Alzheimer’s & Dementia

Filter Your Results




Phase 2 Confirmatory Trial of Bryostatin-1 for Alzheimer’s Disease Enrolls First Patient

Monday, July 16, 2018—The first individual has been enrolled into a confirmatory phase 2 clinical trial of bryostatin-1 (Neurotrope, New York, NY) for the treatment of persons with Alzheimer’…

IncobotulinumtoxinA Approved for Treatment of Excessive Drooling

Friday, July 13, 2018—The Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for incobotulinumtoxin A (Xeomin; Merz, Raleigh, NC) for the treatmen…

Can Patients Unique Brain Imaging Fingerprints Direct Clinical Management?

Tuesday, July 10, 2018—Researchers for the Alzheimer's Disease Neuroimaging Initiative from the Montreal Neurology Institute and Hospital (Montreal, Canada) have published results in the journal…

Positive Results for Potential Alzheimer’s Disease Treatment in Phase 2 Trial

Thursday, July 05, 2018—In one of the first late-stage studies to demonstrate potential disease modifying effects for the treatment of persons with Alzheimer’s disease, a monoclonal antibody to…

Eisai Inc Launching Center for Genetics-Guided Dementia Discovery Center

Thursday, June 14, 2018—Eisai Inc (Woodcliff Lake, NJ), the U.S. pharmaceutical subsidiary of Eisai Co, Ltd, has announced that the company is committing over $100 million as an initial investment to…

Clinical Trials for Lanabecestat for Treatment of Alzheimer’s Disease Discontinued

Tuesday, June 12, 2018—Phase 3 clinical trials for lanabecestat (Lilly, Indianapolis, IN and AstraZeneca, Wilmington, DE) for the treatment of patients with Alzheimer’s disease (AD) are being …

Lester E. Potts, An Artist Who Had Alzheimer’s Disease

June 2018— The paintings on the cover and here were created by Lester E. Potts, Jr. (1928 -- 2007), who had Alzheimer’s disease. After his diagnosis, Lester became a client at …

Epilepsy in Patients With Alzheimer’s Disease

G. Peter Gliebus, MD; Ahmad Al-Sibai, MD; and Michelle L. Dougherty, MD

June 2018—Providers should have a high index of suspicion for seizure disorders in patients with Alzheimer’s disease.


Contact Info

For advertising rates and opportunities:
Wendy Terry

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.